Better Ideas ∙
Better Technologies ∙
Better Therapeutics

TriOar is shaping a better,
healthier future for people in need

TriOar is focusing on developing next-generation antibody-based therapeutics including ADC (Antibody Drug Conjugates) and IO (Immuno-oncology) with novel platform technologies. These technologies are expected to improve the therapeutic index by reducing toxicity and improving efficacy simultaneously.

Platform

View More

TriOar's platform technologies are expected to improve a therapeutic index of anti-cancer agents.

TME Targeting
Effector
Enhanced drug delivery.
Reduced side effects.
Tumor Targeting
Antibody
Specifically targets cancer cells.
Tumor Cell
Killer
Novel linker-toxin system induces
rapid cancer cell death.

Pipeline

View More

Biotechnology Research for Innovation

Our know-how, novel platform technologies, and open relationship
with specialists and research partners will speed up.

View More

Antibody-Drug Conjugates

Immuno-oncology

Merit

Global Leading Company

Excellent research infrastructure
World-class R&D infrastructure backed by excellent domestic and foreign experts.
Proprietary core technologies and platforms
Insight and differentiated technologies acquired through years of experience
A clear strategy for novel antibody drug development
Prudent new drug development approach based on sophisticated plans and focused strategy
Diverse partnerships
Opportunities for diverse and strong partnerships

NEWS&NOTICE

View More

What's New in TriOar

Recruit

Grow with
the best people

We stand for the diversity of every voice and the courage to face
challenges for "growing together".

Grow with the best people

Careers
View More
Recruiting Process
View More
CEO. 
Sung Ho Woo
ADDRESS. 
#403, 361-17 Gapcheon-ro, Yuseong-gu, Daejeon, Korea
TEL. 
042-931-3911
FAX. 
042-933-3912
(C)2023 TRIOAR. All Rights Reserved.
SCROLL